Navigation Links
PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013
Date:10/28/2013

INCLINE VILLAGE, Nev., Oct. 28, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2013 financial results for the period ended September 30, 2013, on Wednesday, November 6, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Conference Call Details

To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 93070209. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 93070209.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying over $125 million in 2012 and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
2. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
3. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
4. CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data Standard Released for Public Review
5. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
6. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
7. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
8. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
9. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
10. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
11. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... Iowa (PRWEB) , ... July 17, 2017 , ... ... component of its long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to ... five strategic areas – trait discovery, plant breeding, enabling technologies, biologicals and digital ...
(Date:7/14/2017)... ... 14, 2017 , ... Sonic Manufacturing Technologies is proud to ... a solar system on its roof top. “We will be independent of the ... Raab stated. The company’s proud history of social responsibility and participation in the ...
(Date:7/13/2017)... IN (PRWEB) , ... July 13, 2017 , ... Thousands ... July and August for the National Aeromodeling Championships (Nats). Pilots come to Muncie to ... try to earn spots on US teams that participate in world championships. , RC ...
(Date:7/13/2017)... ... July 13, 2017 , ... Frederick’s first and ... robust growth in the past year after an intensive restructuring. Under the leadership ... Programs and expanded its board of directors to revitalize the organization. As a ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):